For over 15 years, Ginkgo has invested in building and integrating horizontal platform technologies to serve a diverse set of customer programs and needs with efficient and powerful services. Beyond Ginkgo's homegrown capabilities, Ginkgo has acquired over a dozen companies and has deep strategic partnerships with many others in the broader biotechnology ecosystem. As such, Ginkgo is uniquely experienced as a systems integrator, offering customers a robust set of services within a unified R&D experience. Ginkgo is excited to expand this integrated capability set to include a diverse network of technology partners, providing customers access to a much more extensive suite of cutting edge technologies - all powered and enhanced by Ginkgo's flexible automation and data, and integrated into comprehensive programs.
One of the core focus areas for the Technology Network today is AI. As more companies seek to leverage the latest tools in generative AI, having an integrated approach to R&D and building robust feedback loops into computational models has become a critical differentiator, helping to determine project success. Integrating partner models and AI capabilities with Ginkgo's automation stack can help network partners build more robust models that benefit from additional training data and reinforcement learning. Ginkgo is excited to bring this closed-loop capability to network partners and to current and future customers.
Ginkgo's inaugural cohort of technology network partners includes, in alphabetical order: 310.ai is accelerating scientific discovery by giving scientists access to state-of-the art AI via a user-friendly chat interface. 310's platform, 310 CoPilot ties together proprietary AI, industry-standard models, databases, visualizations, and analytics all in one user-friendly chat interface. This enables customers across industries (biotech, pharmaceutical, cosmetics, etc.) to design novel molecules and bring higher performing solutions to market faster.
Avecris has developed SPRING DNA, a non-viral gene delivery system which enables next-generation genetic medicines. SPRING is a transformational platform technology that enables non-viral DNA delivery while precisely regulating gene expression in a cell-type specific way. SPRING is programmable, modular, redosable, stable and sustained.
BioMap is a leading AI company dedicated to driving innovation in the life sciences sector, leveraging AI to unmask nature's rules and generate proteins for a wide range of therapeutic and industrial applications. BioMap is a pioneer in Large Biology Language Models, having developed the world's largest 100Bn+ parameters biology foundation model, xTrimo, trained on a vast array of multi-dimensional biological data. Combined with a proprietary fine-tuning platform, BioMap can rapidly deploy high-performance task models to support innovation across any horizontal protein design domain or modality. BioMap's AI capabilities are supplemented with a leading team of scientists, disease experts and cutting-edge high-throughput labs. BioMap empowers its partners's R&D ambitions by enabling them to build their own AI models with limited data and leverage BioMap's AI Generated Protein (AIGP) Platform to design novel proteins for frontier healthcare, industry and sustainability needs.
BioSymetrics is a phenomics-driven drug discovery company that integrates clinical and experimental data, using machine learning, to translate human disease biology and advance precision medicines. The company builds translation upfront, using AI and in vivo validation to rapidly discover higher-confidence targets and precision medicines.
bit.bio is a synthetic biology company focused on human cells, advancing medicine and enabling curative treatments. bit.bio's opti-ox precision cell programming technology enables conversion of induced pluripotent stem cells into any desired human cell type in a single step, at industrial scale, while maintaining exceptional purity and consistency. The ioCells research cell product portfolio is opening up new possibilities in research and drug discovery.
Catena Biosciences was spun out of the Doudna and Francis laboratories at
Ceres Nanosciences makes innovative products that capture and concentrate low-abundance analytes from biological samples, enabling early and accurate detection of diseases.
Cradle's software solution empowers biology R&D teams with generative Machine Learning models to design better proteins, faster. Through extensive benchmarking and in-house wet-lab validation, Cradle's models learn iteratively from small datasets. Cradle's models are able to handle multi property optimization and grow more powerful after every experimental round. As a result, R&D teams that use the Cradle platform need substantially less experimental rounds to meet or exceed a protein's target product profiles. Customers gain access to the platform through a transparent subscription-based pricing model and retain full IP of generated proteins.
Cube Biotech provides a comprehensive range of products and services that address the full spectrum of protein research, from expression and purification to characterization and stabilization.
Culture Biosciences utilizes innovative cloud-connected bioreactors and data science capabilities driving the digital transformation of biomanufacturing. Culture's real-time data analysis and data-driven modeling capabilities enable clients to accelerate their biomanufacturing screening and optimization work.
EVQLV helps researchers working in antibodies, CARs, bi/multi-specifics, and ADCs who want to quickly incorporate AI to address discovery and engineering challenges.
FabricNano is a biotechnology company developing a way to transform industrial chemical processes using cell-free biomanufacturing. Its advanced, flexible and easily-scalable platform produces highly stable and performant biocatalysts to enable profitable production of sustainable and bio-based chemicals.
Form Bio provides award-winning software and AI solutions for cell and gene therapy leaders. By combining data, technology and expertise, Form's solutions accelerate timelines from discovery to clinic by providing drug developers with rapid in silico characterization, prediction, simulation and optimization of their therapeutics-enabling higher yields, enhanced safety and shorter, less expensive development cycles. With cross-disciplinary expertise spanning software engineering, biology, bioinformatics and data science, the Form Bio team collaborates closely with customers on their most pressing and strategic challenges and opportunities.
Jumpcode Genomics uses its proprietary CRISPRclean technology to remove unwanted sequences, allowing researchers worldwide to extract greater insights. The company combines CRISPR-based technology and next-generation sequencing (NGS) to search for novel signals, increase sensitivity, and allow access to a range of sample types to broaden the understanding of human biology in fields from research to clinical applications including infectious disease and oncology.
Leveragen is a
Mediphage has developed a proprietary and scalable manufacturing process using E.coli to produce ministring DNA (msDNA), a high-fidelity linear covalently closed (LCC) DNA vector. msDNA can be used across a broad range of gene therapy modalities, including redosable non-viral gene therapy, in vivo and ex vivo gene editing, DNA vaccines, and as a starting material for the manufacturing of high fidelity viral vectors (rAAV, lentiviral) and mRNA.
Medium Biosciences has a mission to build the fastest and most accurate models of biology to cure all diseases, better understand nature and create lasting abundance. Its software platform uses custom AI models to help customers create novel, better biomolecules by simulating their biophysical properties and identifying the most promising ones to be tested in the lab.
Menten.ai is developing generative AI to design next-generation cyclic peptide therapeutics for challenging drug targets beyond the reach of small molecules and biologics. It's the first platform capable of designing potent and membrane-permeable macrocycles in a matter of days. The team has shown in vitro and in vivo validation of their platform for complex drug targets including protein-protein interfaces (PPIs) and intracellular targets.
NeuImmune is a biopharmaceutical company developing innovative vaccines and biopharmaceuticals through precision glycoengineering and delivery of biologics that address important medical and public health needs. The company is committed to providing safe and more effective prophylactic and therapeutic treatments based on its novel biomanufacturing and delivery platforms.
Phase Genomics develops cutting-edge tools for discovery and diagnostics in cancer and infectious disease, using their proprietary ultra-long-range genome sequencing technology. Their microbiome discovery platform enables the deepest view of complex microbial communities possible with current tools. Phase Genomics has generated the largest atlas of bacteriophage and antibiotic resistance reservoirs and is applying this information to combat microbial threats and isolate therapeutic proteins.
ProteoNic offers premium vector technology driving high level production of biologics as well as increased viral titers for cell and gene therapy applications. The technology is broadly applicable across cell lines and product classes, including complex molecules which are difficult to express by conventional technology. Application of this technology is designed to enable production of complex molecules at economically viable levels, resolve capacity constraints and reduce manufacturing costs. Applied to viral vectors, it has the capacity to resolve bottlenecks currently associated with lentiviral and AAV production.
Resilience is a technology-focused biomanufacturing company dedicated to broadening access to complex medicines. Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions across biologics, vaccines, nucleic acids, cell and gene therapy to ensure the treatments of today and tomorrow can be made quickly, safely, andat-scale. By continuously advancing the science of biopharmaceutical manufacturing and development, Resilience seeks to free its partners to focus on the discoveries that improve patients' lives and protect biopharmaceutical supply chains against future disruptions.
Synplogen is a synthetic biology startup spun out of
Turbine AI is building the world's first predictive simulation of patient biology to empower the biopharma industry by informing the right experiments that identify and validate disease driver hidden effects. Turbine's Simulated Cell is an interpretable cell simulation platform that captures patient biology better than currently available models, and is used for in silico experiments at scales impossible in physical assays. The Simulated Cells can be integrated into all steps of biopharma R&D to boost their likelihood of success, from identifying novel targets invisible to high throughput biological screening to optimally targeting existing therapies at the most responsive patients.
WhiteLab Genomics is an AI-based platform for discovery, design, and accelerated development of genomic medicines. By leveraging their proprietary technology, WhiteLab Genomics analyzes complex biological data powered by AI to significantly reduce development timelines and mitigate associated risks. Based on exhaustive datasets, the platform provides in-silico simulations to discover, and design optimized payloads and vectors.
Ginkgo does not have its own product portfolio. As a platform company, Ginkgo makes customer-driven infrastructure investments and is incentivized to make its tools and capabilities available to customers. Ginkgo's programs require the integration of both existing capabilities and new techniques and approaches, whether that means investing in a novel high throughput assay design, a new approach for editing cells, or a fine-tuned AI model to explore a vast design space more efficiently. This approach to biology allows customers to access a range of technical approaches rather than feel constrained by the status quo.
About
Forward-Looking Statements of
This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of Ginkgo's cell programming platform and the capabilities and potential growth of the Ginkgo Technology Network. These forward-looking statements generally are identified by the words 'believe,' 'can,' 'project,' 'potential,' 'expect,' 'anticipate,' 'estimate,' 'intend,' 'strategy,' 'future,' 'opportunity,' 'plan,' 'may,' 'should,' 'will,' 'would,' 'will be,' 'will continue,' 'will likely result,' and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (ii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vi) our ability to realize the expected benefits of merger and acquisition transactions, (vii) the outcome of any legal proceedings against Ginkgo, including as a result of recent acquisitions, (viii) our ability to realize the expected benefits from and the success of our Foundry platform programs, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, and (x) the product development or commercialization success of our customers. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the 'Risk Factors' section of Ginkgo's quarterly report on Form 10-Q filed with the
Contact:
Email: investors@ginkgobioworks.com
Email: press@ginkgobioworks.com
(C) 2024 Electronic News Publishing, source